轻中度COVID-19的药物治疗:系统综述与网络Meta分析
该系统综述与网络Meta分析纳入187项随机对照试验,比较轻中度COVID-19的药物疗效,发现奈玛特韦-利托那韦和瑞德西韦可能减少住院,全身性糖皮质激素和莫诺拉韦可能减少住院,多种药物可能缩短症状缓解时间。
要点
- 与标准治疗相比,奈玛特韦-利托那韦可能减少住院(每1000人减少25例,95%CI 28至20,中等确定性)。
- 与标准治疗相比,瑞德西韦可能减少住院(每1000人减少21例,95%CI 28至7,中等确定性)。
- 与标准治疗相比,阿奇霉素可能缩短症状缓解时间(平均差异减少4天,95%CI 5至3,中等确定性)。
核心结论
- 奈玛特韦-利托那韦和瑞德西韦可能减少住院,全身性糖皮质激素和莫诺拉韦可能减少住院。
- 包括全身性糖皮质激素和莫诺拉韦在内的多种药物可能缩短症状缓解时间。
研究设计与样本
- 系统综述与网络Meta分析,纳入187项随机对照试验(共259项试验、166230例患者中的72%被纳入分析)。
- 检索数据源包括COVID-19 L-OVE(2023年1月1日至2024年5月19日)、WHO COVID-19数据库(截至2023年2月17日)和6个中文数据库(截至2021年2月20日),纳入2019年12月1日至2023年6月28日之间识别的研究。
- 采用贝叶斯网络Meta分析,使用改良的Cochrane偏倚风险2.0工具评估偏倚风险,使用GRADE方法评估证据确定性。
主要发现
- 与标准治疗相比,奈玛特韦-利托那韦可能减少住院(每1000人减少25例,95%CI 28至20,中等确定性),瑞德西韦可能减少住院(每1000人减少21例,95%CI 28至7,中等确定性)。
- 莫诺拉韦和全身性糖皮质激素可能减少住院(低确定性)。
- 与标准治疗相比,阿奇霉素可能缩短症状缓解时间(平均差异减少4天,95%CI 5至3,中等确定性),全身性糖皮质激素、法匹拉韦、莫诺拉韦和乌米诺韦可能缩短症状持续时间(中等至高度确定性)。
- 与标准治疗相比,仅洛匹那韦-利托那韦增加导致停药的不良反应。
关键数值与推荐
- 药物按GRADE指导从最有益到最有害分组。
- 奈玛特韦-利托那韦:每1000人减少住院25例(95%CI 28至20),中等确定性。
- 瑞德西韦:每1000人减少住院21例(95%CI 28至7),中等确定性。
- 阿奇霉素:症状缓解时间平均减少4天(95%CI 5至3),中等确定性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本综述未注册。
- 研究方案在补充材料中公开。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effects of treatments for mild or moderate (that is, non-severe) coronavirus disease 2019 (covid-19). DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Covid-19 Living Overview of Evidence Repository (covid-19 L-OVE) by the Epistemonikos Foundation, a public, living repository of covid-19 articles, from 1 January 2023 to 19 May 2024. The search also included the WHO covid-19 database (up to 17 February 2023) and six Chinese databases (up to 20 February 2021). The analysis included studies identified between 1 December 2019 and 28 June 2023. STUDY SELECTION: Randomised clinical trials in which people with suspected, probable, or confirmed mild or moderate covid-19 were allocated to drug treatment or to standard care or placebo. Pairs of reviewers independently screened potentially eligible articles. METHODS: After duplicate data abstraction, a bayesian network meta-analysis was conducted. Risk of bias was assessed by use of a modification of the Cochrane risk of bias 2.0 tool, and the certainty of the evidence using the grading of recommendations assessment, development, and evaluation (GRADE) approach. For each outcome, following GRADE guidance, drug treatments were classified in groups from the most to the least beneficial or harmful. RESULTS: Of 259 trials enrolling 166 230 patients, 187 (72%) were included in the analysis. Compared with standard care, two drugs probably reduce hospital admission: nirmatrelvir-ritonavir (25 fewer per 1000 (95% confidence interval 28 fewer to 20 fewer), moderate certainty) and remdesivir (21 fewer per 1000 (28 fewer to 7 fewer), moderate certainty). Molnupiravir and systemic corticosteroids may reduce hospital admission (low certainty). Compared with standard care, azithromycin probably reduces time to symptom resolution (mean difference 4 days fewer (5 fewer to 3 fewer), moderate certainty) and systemic corticosteroids, favipiravir, molnupiravir, and umifenovir probably also reduce duration of symptoms (moderate to high certainty). Compared with standard care, only lopinavir-ritonavir increased adverse effects leading to discontinuation. CONCLUSION: Nirmatrelvir-ritonavir and remdesivir probably reduce admission to hospital, and systemic corticosteroids and molnupiravir may reduce admission to hospital. Several medications including systemic corticosteroids and molnupiravir probably reduce time to symptom resolution. SYSTEMATIC REVIEW REGISTRATION: This review was not registered. The protocol is publicly available in the supplementary material.
引用
- Ibrahim S, Siemieniuk RAC, Oliveros MJ, et al. Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis. BMJ. 2025. PMID: 40441732. doi:10.1136/bmj-2024-081165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。